Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer

Next Previous
Trial Profile

Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Binimetinib (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 28 Feb 2018 Status changed from recruiting to suspended.
    • 29 Nov 2017 Planned End Date changed from 1 May 2020 to 15 May 2020.
    • 29 Nov 2017 Planned primary completion date changed from 1 May 2020 to 15 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top